Shanghai Rendu Biotechnology Stock Beta
| 688193 Stock | 38.01 0.70 1.81% |
Shanghai Rendu Biotechnology fundamentals help investors to digest information that contributes to Shanghai Rendu's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Rendu's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Rendu stock.
Shanghai | Beta |
Shanghai Rendu Biotechnology Company Beta Analysis
Shanghai Rendu's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Shanghai Rendu Beta | 0.2 |
Most of Shanghai Rendu's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Rendu Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Shanghai Rendu Biotechnology has a Beta of 0.202. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The beta for all China stocks is notably lower than that of the firm.
Shanghai Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Rendu's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Rendu could also be used in its relative valuation, which is a method of valuing Shanghai Rendu by comparing valuation metrics of similar companies.Shanghai Rendu is currently under evaluation in beta category among its peers.
As returns on the market increase, Shanghai Rendu's returns are expected to increase less than the market. However, during the bear market, the loss of holding Shanghai Rendu is expected to be smaller as well.
Shanghai Fundamentals
| Return On Equity | 0.0227 | ||||
| Return On Asset | -0.0062 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 875.41 M | ||||
| Shares Outstanding | 40 M | ||||
| Shares Owned By Insiders | 60.11 % | ||||
| Shares Owned By Institutions | 5.85 % | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 8.50 X | ||||
| Revenue | 164.41 M | ||||
| Gross Profit | 141.86 M | ||||
| EBITDA | 2.87 M | ||||
| Net Income | 8.26 M | ||||
| Total Debt | 2.93 M | ||||
| Book Value Per Share | 23.95 X | ||||
| Cash Flow From Operations | 17.19 M | ||||
| Earnings Per Share | 0.54 X | ||||
| Number Of Employees | 358 | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 1.52 B | ||||
| Total Asset | 1.05 B | ||||
| Retained Earnings | 136.46 M | ||||
| Working Capital | 820.69 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 1.05 B | ||||
| Last Dividend Paid | 0.3 |
About Shanghai Rendu Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Rendu Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Rendu using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Rendu Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Rendu financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Rendu security.